Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP530 | DOI: 10.1530/endoabs.49.EP530

1Servicio de Endocrinología y Nutrición, Hospital Dr. Negrín de Gran Canaria, Las Palmas de Gran Canaria, Spain; 2CAP Rambla Terrassa, HUMT, Barcelona, Spain.

Objectives: The AMANDHA randomized study (PROBE design) showed that the addition of Manidipine 20 mg vs Amlodipine 10 mg for 2 years in 91 hypertensive type 2 diabetic patients with persistent microalbuminuria, uncontrolled with a renin-angiotensin system inhibitor (given full-dose for at least the 6 previous months) was more effective in reducing albuminuria in spite of similar blood pressure control. Patients with significant renal impairment (PlCr >1.4 mg/dl in women and >1.5 in men) had been excluded. However, no data were published on the progression of renal dysfunction, with only PlCr values reported, which were not significantly different. We undertook to establish if there were differences in glomerular filtration rate (GFR) progression.

Methods: Post-hoc analysis of AMANDHA. GFR was estimated by the MDRD-4 equation for each individual measurement. Point-to-point GFR were compared by unpaired t-test and progression was compared by the Kruskal-Wallis test. (non-parametric ANOVA). Values are given as mean (± standard error).

Results: Baseline GFR were 67.3 (±5.2) and 70.2 (±5.0) ml/min/1.73 m2 with Manidipine and Amlodipine, respectively; at 6 months they were 68.6 (±5.6) and 69.5 (±5.3), and at 2 years 66.9 (±4.7) and 65.5 (±5.0). During follow-up, patients treated with Manidipine lost 0.4 (±3.9) ml/min/1.73 m2 of FGR vs 4.7 (±5.2) with Amlodipine. Point-to-point GFR were not significantly different between the groups, but GFR loss after 2 years was lower with Manidipine (P=0.032).

Conclusions: The previously published data of AMANDHA showed a markedly greater albuminuria reduction (about 40% more) with Manidipine vs Amlodipine, which was attributed to efferential arteriole dilatation. The present post-hoc analysis also shows a better preservation of renal function with Manidipine. These results strengthens the case for combined treatment with Manidipine and a renin-angiotensin system blocker in hypertensive type 2 diabetic patients with persistent microalbuminuria.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.